Zn-DDC

PreclinicalSmall molecule

TThe Royal Wolverhampton Hospitals NHS Trust

Zn-DDC is one of 40 small molecule programs targeting Multiple Myeloma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaActive, not recruiting

Multiple MyelomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

258 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Belamaf

GSK

Phase 3

39 2

Empliciti

Bristol-Myers Squibb

Phase 3

43 3

Keytruda

Merck & Co.

Phase 3

17 4

Venclexta

AbbVie

Phase 3

17 5

Opdivo

Bristol-Myers Squibb

Phase 3

11 6

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

28 7

Neulasta

Amgen

Phase 3

5 8

Cytosar

Teva

Phase 3

4 9

Busulfex

Akero Therapeutics

Phase 3

14 10

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Recruiting

Multiple Myeloma

NCT04234022

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

Recruiting·TThe Royal Wolverhampton Hospitals NHS Trust··NCT04234022·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zn-DDC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zn-DDC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zn-DDC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Royal Wolverhampton Hospitals NHS Trust company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe Royal Wolverhampton Hospitals NHS Trust

Zn-DDC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News